Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

Keyphrases

• Losartan 100%
• Type 1 Diabetic Patient 100%
• Diabetic Nephropathy 100%
• Renoprotective Effect 100%
• Angiotensin Receptor Blockade 100%
• Enalapril 75%
• Albuminuria 62%
• Angiotensin I-converting Enzyme Inhibition 62%
• Mean Arterial Pressure 37%
• Angiotensin II (Ang II) 37%
• Renin-angiotensin System 25%
• Blood Pressure 25%
• Glomerular Filtration Rate 25%
• Bradykinin 25%
• 1 Receptor 25%
• No Significant Difference 12%
• Placebo 12%
• Receptor Antagonist 12%
• Hemoglobin A1c (HbA1c) 12%
• New Drugs 12%
• Randomized Double-blind 12%
• Hypertension Management 12%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 12%
• Renal Effects 12%
• Pressure Filtration 12%
• Specific Interventions 12%
• Kidney Function 12%
• Proteinuria 12%
• Sodium Intake 12%
• 24-hour Blood Pressure 12%
• Hemodynamic Effects 12%
• Serum Potassium 12%
• Pressure Function 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Losartan 100%
• Diabetes Mellitus 100%
• Diabetic Nephropathy 100%
• Angiotensin Receptor 100%
• Enalapril 75%
• Angiotensin I 75%
• Dipeptidyl Carboxypeptidase 62%
• Albuminuria 62%
• Enzyme Inhibition 62%
• Angiotensin II 37%
• Renin 25%
• Angiotensin 25%
• Bradykinin 25%
• Scanning Electron Microscopy 25%
• Receptor 12%
• Placebo 12%
• Receptor Antagonist 12%
• Isotopes of Potassium 12%
• Dipeptidyl Carboxypeptidase Inhibitor 12%
• Proteinuria 12%
• Hypertension 12%
• Sodium 12%
• Potassium 12%